课题基金 / 基金详情

Signal transduction of IL-6 in myeloma cells

Signal transduction of IL-6 in myeloma cells
IL-6在骨髓瘤细胞中的信号转导
批准号:
09044301
负责人:
YOSHIZAKI Kazuyuki
金额:
$3.07万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for international Scientific Research
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998

项目摘要

项目成果

YOSHIZAKI Kazuyuki的其他基金

相似基金

相关文献

中文摘要
翻译
白细胞介素-6(IL-6)被认为是多发性骨髓瘤(MM)细胞的一种有效的生长因子。它还可以防止一些骨髓瘤细胞由皮质类固醇和Fas抗原(CD95)交联诱导的自由凋亡。IL-6已被证明使用两种胞浆内信号转导途径:(i) gpl30 * Ras * MARK * NF-IL6。(ii) gpl30 * JAK * STAT3和/或STAT1在本研究的第一年,我们的同事Dr.Anderson阐明了前者通路用于生长刺激信号,我们也证明了STAT3的一个靶基因产物可以抑制STAT3的磷酸化蛋白,并被命名为STATs-induced STAT inhibitor-1 (SSI-1)。SSI-1似乎是JAK-STAT信号通路的负反馈因子。为了阐明SSI-1及其与SSI-1具有构建同源性的家族分子在MM发病机制中的可能作用,我们研究了它们在6株骨髓瘤细胞系中对IL-6刺激的表达和诱导。发现IL-6酪氨酸磷酸化STAT3的失能与SSI-1的组成性表达密切相关,而SSI-2、SSI-3、SSI-4和SSI-6的组成性表达无关,提示SSI-1的异常表达可能导致部分骨髓瘤细胞中IL-6的JAK-STAT信号通路受损。在OCI-My5细胞中,si -1的人工组成性表达显著抑制STAT3的磷酸化,OCI-My5细胞代表STAT3可被lL-6磷酸化的MM细胞。相反,通过在ARH77中引入反义SSI-1基因,STAT3的酪氨酸磷酸化得以恢复,ARH77代表了STAT3不能被IL-6磷酸化的MM细胞。这些数据证实,在一些MM细胞系中,SSI-1的非调控构成性表达导致对IL-6缺乏反应。需要进一步的研究来了解SSI-1转录解除管制的机制。
英文摘要
Interleukin-6(IL-6) is known to be a potent growth factor of multiple myeloma(MM) cells. It also prevents some myeloma cells fremapeptosis induced by corticosteroids, and crosslinking of Fas antigen (CD95). IL-6 has been shown to use two intracytoplasmic signal transducing pathways : (i) gpl3O * Ras * MARK * NF-IL6. (ii) gpl30 * JAK * STAT3 and/or STAT1 In the first year of this study, our collegue Dr.Anderson elucidated that the formrer pathway was used for growth stimulatory signal We also demonstrated that one of the STAT3-target gene products could inhibit the phosphorylatinn of STAT3 and was designated as STATs-induced STAT inhibitor-1 (SSI-1. The SSI-1 appears to act as a negative feedback factor of JAK-STAT signaling pathway. To elucidate a possible role in the pathogenesis of MM of SSI-1 and its family molecules which have a constructive homology with SSI-1, we have examined their expression and induction in six myeloma cell line in response to IL-6 stimulation. Close relation was found between disability in tyrosine-phosphorylation of STAT3 by IL-6 and constitutive expression of SSI-1 but not of SSI-2 SSI-3, SSI-4 or SSI-6, suggesting the abnormal expression of SSI-1 may cause the impaired JAK-STAT signaling of IL-6 in some myeloma cells. Artificial constitutive expression of SSI-1 markedly suppressed STAT3 phosphorylation in OCI-My5 cells which represent MM cells whose STAT3 could be phosphorylated by lL-6. On the contrary, tyrosime-phosphorylation of STAT3 was restored by introducing anti-sense SSI-1 gene in ARH77 which represent MM cells whose STAT3 could not be phosphorylated by IL-6.These data confirmed deregulated constitutive expression of SSI-1 caused the lack of response to IL-6 in some MM cell lines.Further study will be required to understand the mechanisms for such transcriptional deregulation of SSI-1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nishimoto N,Yoshizaki K,KishimotoT: "Anticytokine therapy in autoimmune diseases." Internal Medicine. (in press). (1999)
Nishimoto N、Yoshizaki K、KishimotoT:“自身免疫性疾病中的抗细胞因子疗法。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nishimoto, N., Y.Shima, K.Yoshizaki, T.Kishimoto.: "Myeloma Bology and Therapy-Present Status and Future Development-B.Barlogie,ed.Hematology/Oncology Clinics of North America." W.B.SAUNDERS COMPANY, 159-172 (1997)
Nishimoto, N.、Y.Shima、K.Yoshizaki、T.Kishimoto.:“骨髓瘤生物学和治疗的现状和未来发展-B.Barlogie,ed.北美血液学/肿瘤学诊所。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ogawa, H., H.Ito, A.Takeda, S.Kanazawa, et al: "Universal Skew of T Cell Receptor (TCR) VE Usage for Crohn's Disease (CrD)." Biochem.Biophy.Res.Communications.(1998)
Okawa, H.、H.Ito、A.Takeda、S.Kanazawa 等人:“T 细胞受体 (TCR) VE 在克罗恩病 (CrD) 中的普遍偏差。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Matsuno H, Sawai T, Nezuka T, Uzuki M, Tsuji H, Nishimoto N, Yoshizaki K: "Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6-receptor monoclonal antibody-use of Rheumatoid Arthritis tissues implants in the SCID mouse model" Arthrit
Matsuno H、Sawai T、Nezuka T、Uzuki M、Tsuji H、Nishimoto N、Yoshizaki K:“用抗重塑人白细胞介素 6 受体单克隆抗体治疗类风湿性滑膜炎 - 在 SCID 小鼠模型中使用类风湿性关节炎组织植入物
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
6
    The roles of pro-inflammatory cytokines on induction of acute phase proteins in inflammatory diseases
    • 批准号:
      15390314
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $7.42万
    • 财政年份:
      2003
    • 负责人:
      YOSHIZAKI Kazuyuki
    • 依托单位:
    国内基金
    海外基金
    早期滋养型肠内营养联合益生菌对重症卒中患者喂养耐受性及TNF-α/IL-6水平的影响研究
    七氟烷通过调控IL-6/FSP1轴抑制心肌铁死亡减轻心肌缺血再灌注损伤的机制研究
    • 批准号:
      JCZRLH202601296
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    盐酸小檗碱抑制NF-κB/IL-6/STAT3信号通路重塑免疫微环境并增敏肺癌免疫治疗的研究
    • 批准号:
      JCZRLH202600985
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    双歧杆菌与消退素RvD1协同调控IL-6/STAT3/Notch信号轴介导结肠癌EMT及免疫调节的机制研究
    • 批准号:
      JCZRLH202601410
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位: